Legality of the Leveraged Lending Guidance is Questioned
Limits on Creditors’ Remedies Against Solvent Debtors Echoed in the Quadrant Litigation
Please use the form below to search for any relevant publications pertaining to your specific needs. If you would like to be added to Kramer Levin's publications distribution list, please click onto the Publications Sign Up in the right side bar.
Kramer Levin represented Cantor Fitzgerald & Co., as the Lead Book-Running Manager, in a shelf takedown for 23,625,084 shares of the common stock of Sorrento Therapeutics Inc., a clinical-stage biopharmaceutical company. The offering included the option for certain underwriters to purchase up to an aggregate of 3,543,763 additional shares.
The Kramer Levin team consisted of Corporate partners Richard E. Farley and Christopher S. Auguste, and associates Jenny R. Leon and Joel Pietrzak.